21 May 2019

Mereo BioPharma Group plc

 ("Mereo" or the "Company")

Notification of Director and other PDMR Dealings

London, May 21, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, on May 20, 2019 granted incentive awards as set out below to persons discharging managerial responsibilities (PDMRs). All the awards were granted for nil consideration and shall ordinarily be forfeit (to the extent unvested) upon cessation of service.

Options to acquire American Depositary Shares ("ADSs") at an exercise price of $5.40 per ADS (Fair Market Value at grant) under the Mereo BioPharma Group plc 2019 Equity Incentive Plan (an employees' share scheme):

Name of PDMR

Position

Number of ADSs over which Option granted

Denise Scots-Knight

Chief Executive Officer

87,500

Alastair MacKinnon

Chief Medical Officer

27,500

Richard Jones

Chief Financial Officer

27,500

Charles Sermon

General Counsel

27,500

Wills Hughes-Wilson

Head of Patient Access and Commercial Planning

18,000

John Richard

Head of Corporate Development

27,500

 

These Options shall normally vest and become exercisable as to one quarter on the first anniversary of their grant date and, thereafter, as to the balance in equal monthly installments over the three-year period following such anniversary.

 

Awards to either acquire ADSs at an exercise price of $5.40 per ADS (Fair Market Value at grant) or, at the Company's discretion, receive a cash amount equal to the excess, if any, over the exercise price of their Fair Market Value on the exercise date:

 

Name of PDMR

Position

Number of ADSs over which Award granted

Peter Fellner

Chairman

5,500

Anders Ekblom

Director

5,500

Peter Bains

Director

5,500

Kunal Kashyap

Director

5,500

Paul Blackburn

Director

5,500

Deepa Pakianathan

Director

5,500

Michael Wyzga

Director

5,500

 

These awards shall vest in equal monthly installments over the year following their grant date.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The forms required under the EU Market Abuse Regulation follow.

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Denise Scots-Knight

 

2

Reason for the notification

 

a)

Position/status

Chief Executive Officer

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

87,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Alastair MacKinnon

 

2

Reason for the notification

 

a)

Position/status

Chief Medical Officer

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Richard Jones

 

2

Reason for the notification

 

a)

Position/status

Chief Financial Officer

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Charles Sermon

 

2

Reason for the notification

 

a)

Position/status

General Counsel

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Wills Hughes-Wilson

 

2

Reason for the notification

 

a)

Position/status

Head of Patient Access and Commercial Planning

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

18,000

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

John Richard

 

2

Reason for the notification

 

a)

Position/status

Head of Corporate Development

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT)

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

27,500

 

 

d)

Aggregated information: volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Peter Fellner

 

2

Reason for the notification

 

a)

Position/status

Chairman

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Anders Ekblom

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Peter Bains

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Kunal Kashyap

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Paul Blackburn

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Deepa Pakianathan

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Michael Wyzga

 

2

Reason for the notification

 

a)

Position/status

Director

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS), EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

b)

Nature of the transaction

GRANT OF AN AWARD (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 NON-EMPLOYEE EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$5.40 PER ADS (FAIR MARKET VALUE AT GRANT). ON EXERCISE, THE COMPANY HAS DISCRETION EITHER TO DELIVER ADSS OR MAKE A CASH PAYMENT EQUAL TO ANY EXCESS OF THEIR FAIR MARKET VALUE OVER THE EXERCISE PRICE

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

NIL

5,500

 

 

d)

Aggregated information:  volume, Price

NOT APPLICABLE - SINGLE TRANSACTION

e)

Date of the transaction

May 20, 2019

 

f)

Place of the transaction

Outside of a trading venue

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END